Connecticut Medic, are you in agreement that if one IV dose of leronlimab had been the first dose administered followed by three successive weeks of subQ doses that CD 12 would have been a resounding success not only in the critical population, but also among the patients in severe condition and that the trial on the whole would have had results warranting the granting of EUA?
News 
Market Data 
Discover 
